Glipizide

Overview

Glipizide (Glucotrol®) is a second-generation sulfonylurea oral antidiabetic agent occasionally used in veterinary medicine for selected cats with type II diabetes mellitus. It is intended only for stable, nonketotic diabetic cats that retain functional pancreatic beta cells and can be closely monitored throughout therapy.

In feline medicine, glipizide is generally reserved for situations in which owners decline insulin therapy or for carefully selected cats that appear relatively well controlled on low insulin doses and may be candidates for transition to oral therapy. Insulin therapy remains the preferred first-line treatment for newly diagnosed diabetic cats because it provides superior glycemic control and offers a greater chance of diabetic remission.

Glipizide is not recommended in dogs because canine diabetic patients are typically insulin-deficient by the time hyperglycemia develops, making sulfonylurea therapy ineffective in most cases.

Mechanism of Action (MOA): Glipizide stimulates pancreatic beta cells to increase endogenous insulin secretion. Additional effects may include improved peripheral tissue sensitivity to insulin and reduced hepatic glucose production. Clinical response depends on the presence of residual functional beta cells, which explains why only a subset of diabetic cats respond adequately to therapy.

Indications

Glipizide is used in selected cats with type II diabetes mellitus when residual pancreatic beta cell function is present and close monitoring is possible. It should only be considered in stable, nonketotic diabetic cats with mild to moderate clinical signs and is generally reserved for situations in which insulin therapy is declined or impractical.

• Type II diabetes mellitus in cats: Used as an adjunct to dietary management in carefully selected cats with nonketotic diabetes mellitus and preserved endogenous insulin production.
• Alternative when insulin therapy is declined: May be considered when owners are unable or unwilling to administer insulin injections, provided the cat is clinically stable and can be closely monitored.
• Transition from low-dose insulin therapy: A therapeutic trial may be attempted in some cats that appear relatively well controlled on low insulin doses and may no longer require injectable insulin.
• Adjunct to dietary therapy: Glipizide should always be combined with appropriate dietary management and weight control strategies to improve glycemic regulation.
• Monitoring-based therapeutic trial: Because only a portion of cats respond adequately, glipizide is typically used as a monitored therapeutic trial with reassessment of blood glucose control over several weeks.

Dosage (Reference)

Cat

Glipizide is rarely recommended in cats and should only be used in carefully selected diabetic patients with residual pancreatic beta cell function. Treatment success is variable, and response may take several weeks to fully evaluate. Dietary management and close monitoring are essential throughout therapy.

Dog

Glipizide is not recommended in dogs. Most canine diabetic patients are insulin-deficient by the time clinical diabetes mellitus is diagnosed, making sulfonylurea therapy ineffective in the majority of cases.

Warnings & Precautions

Glipizide should only be used in carefully selected diabetic cats with preserved pancreatic beta cell function and the ability to undergo close clinical monitoring. Because treatment failure, hypoglycemia, and hepatic toxicity may occur, regular reassessment is essential throughout therapy.

• Absolute insulin deficiency: Contraindicated in cats with absolute insulin deficiency, diabetic ketosis, or diabetic ketoacidosis, as these patients require insulin therapy.
• Not recommended in dogs: Glipizide is generally ineffective in canine diabetes mellitus because most diabetic dogs are insulin-deficient at diagnosis.
• Risk of hypoglycemia: Sulfonylureas can produce clinically significant hypoglycemia, particularly with reduced food intake, overdose, or concurrent illness.
• Delayed or inadequate response: Clinical improvement may require several weeks, and some cats may fail therapy after an initial response due to progressive beta cell exhaustion.
• Hepatic disease: Use cautiously in cats with hepatic dysfunction because glipizide is extensively metabolized by the liver and may increase the risk of hepatotoxicity.
• Renal dysfunction: Use cautiously in cats with impaired renal function because altered drug clearance may increase the risk of adverse effects and hypoglycemia.
• Endocrine disorders: Untreated adrenal, pituitary, or thyroid disorders may interfere with glycemic control and reduce treatment efficacy.
• Debilitated patients: Use cautiously in malnourished, debilitated, febrile, or chronically vomiting cats because these patients may be more susceptible to hypoglycemia.
• Sulfonamide sensitivity: Cats with hypersensitivity to sulfonamide derivatives may also react adversely to glipizide.
• Insulin resistance: Glipizide appears less effective in cats with significant insulin resistance or concurrent endocrinopathies that antagonize insulin action.
• Progressive beta cell damage: Persistent hyperglycemia and increased amyloid deposition may contribute to continued pancreatic beta cell destruction over time.
• Monitoring requirements: Regular blood glucose evaluation, urine monitoring, CBCs, and serum chemistry testing are necessary to detect treatment failure, hypoglycemia, or liver toxicity early.
• Drug name confusion: Do not confuse glipizide with glimepiride or glyburide, as medication errors may result in inappropriate dosing or treatment complications.

Drug Interactions

Most clinically relevant interactions with glipizide involve altered blood glucose regulation, increased risk of hypoglycemia, or changes in plasma protein binding. Careful monitoring of blood glucose concentrations is recommended whenever glipizide is combined with other medications that may affect glycemic control.

• Azole antifungals (e.g., fluconazole, itraconazole, ketoconazole): May increase plasma concentrations of glipizide and enhance the risk of hypoglycemia.
• Beta-adrenergic blockers (e.g., atenolol, propranolol): May potentiate hypoglycemic effects and may mask clinical signs of hypoglycemia.
• Chloramphenicol: May displace glipizide from plasma protein binding sites and increase drug effects.
• Cimetidine: May enhance the hypoglycemic effect of glipizide.
• Corticosteroids: May antagonize insulin activity and reduce the effectiveness of glipizide therapy.
• Thiazide diuretics: May decrease hypoglycemic efficacy and worsen glycemic control.
• Fluoroquinolones (e.g., enrofloxacin, ciprofloxacin): May increase the risk of either hypoglycemia or hyperglycemia.
• Monoamine oxidase inhibitors (MAOIs): May potentiate hypoglycemic effects when used concurrently.
• Phenothiazines (e.g., acepromazine, chlorpromazine): May reduce the hypoglycemic efficacy of glipizide.
• Sympathomimetic agents: May antagonize glucose-lowering effects and reduce treatment efficacy.
• Thyroid hormone supplementation: May reduce the hypoglycemic response to glipizide.
• Sulfonamides and warfarin: May displace glipizide from plasma proteins and increase the risk of hypoglycemia.
• Probenecid: May potentiate the hypoglycemic effect of glipizide.
• Niacin and isoniazid: May reduce glucose-lowering efficacy and impair diabetic control.
• Ethanol: May increase the risk of adverse reactions and abnormal glucose regulation; gastrointestinal effects and disulfiram-like reactions have been reported in humans.

Side Effects & Overdose

Side Effects

Adverse effects associated with glipizide in cats are primarily related to gastrointestinal intolerance, hypoglycemia, or hepatic toxicity. Many adverse reactions are dose-dependent and may improve with dose reduction or discontinuation of therapy.

• Gastrointestinal effects: Anorexia and vomiting are the most commonly reported adverse effects and occur in approximately 15% of treated cats.
• Vomiting after dosing: Vomiting often develops shortly after administration and may resolve within several days of continued therapy.
• Hypoglycemia: Mild to moderate hypoglycemia may occur, especially in cats with reduced appetite, concurrent illness, or excessive dosing.
• Weakness and lethargy: Clinical signs associated with hypoglycemia may include weakness, depression, unsteadiness, or collapse.
• Neurologic signs: Severe hypoglycemia may rarely result in seizures, muscle twitching, rear limb weakness, or coma.
• Hepatotoxicity: Elevated liver enzymes and cholestatic liver injury have been reported in some cats receiving glipizide therapy.
• Icterus (jaundice): Cats developing icterus should have therapy discontinued immediately and undergo reassessment of liver function.
• Increased amyloid deposition: Long-term use may contribute to pancreatic amyloid accumulation and progressive beta cell dysfunction.
• Allergic reactions: Hypersensitivity reactions are uncommon but may occur in cats sensitive to sulfonamide derivatives.

Overdose

The primary concern following glipizide overdose is profound or prolonged hypoglycemia. Clinical severity depends on the dose ingested, nutritional status, and the patient’s ability to maintain blood glucose concentrations.

• Severe hypoglycemia: The most important toxic effect and may develop rapidly after overdose.
• Neurologic complications: Tremors, seizures, weakness, ataxia, stupor, or coma may occur secondary to severe hypoglycemia.
• Gastrointestinal signs: Vomiting, anorexia, and lethargy may accompany overdose episodes.
• Monitoring requirements: Blood glucose concentrations should be monitored closely for prolonged periods after overdose exposure.
• Dextrose supplementation: Parenteral glucose therapy may be required to correct and maintain normal blood glucose concentrations.
• Supportive care: Additional supportive treatment may include fluid therapy, electrolyte monitoring, and nutritional support.
• Large overdoses: Massive exposures may require extended hospitalization and repeated glucose supplementation due to recurrent hypoglycemia.
• Decontamination: Gastrointestinal decontamination may be considered in recent oral overdoses when clinically appropriate.

Key Notes

Practical clinical points that help optimize the safe and effective use of glipizide in feline diabetic patients:

• Response variability: Only a minority of diabetic cats respond adequately to oral sulfonylurea therapy, so treatment expectations should remain realistic.
• Early reassessment is essential: Cats that fail to show meaningful clinical improvement within several weeks should be transitioned to insulin therapy rather than continuing ineffective oral treatment.
• Best candidates: Cats with mild clinical signs, stable body condition, and residual endogenous insulin production are the most likely to benefit.
• Diet strongly influences success: Consistent feeding schedules and appropriate diabetic diets significantly improve the likelihood of achieving acceptable glycemic control.
• Owner compliance matters: Successful therapy depends heavily on owners being able to monitor appetite, body weight, urination patterns, and overall clinical response at home.
• Not a substitute for monitoring: Clinical improvement alone does not guarantee adequate diabetic regulation; laboratory reassessment remains necessary even in apparently stable cats.
• Extended-release products: Extended-release human formulations are generally avoided in veterinary patients because dosing flexibility is limited.
• Therapeutic goals: The primary aim is improving quality of life and reducing clinical signs rather than achieving perfectly normal blood glucose values.